Patent intelligence · US
US 10434100
Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
Patent details — US 10434100
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 8, 2019
- Expiration
- Oct 3, 2039
- Applicant
- Lixte Biotechnology, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/34, A61K31/454, A61K31/496
Quick answer
US 10434100 (Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes) is held by Lixte Biotechnology, Inc.. Status: granted. Granted Oct 8, 2019. Expires Oct 3, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lixte Biotechnology, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/34, A61K31/454, A61K31/496, A61K31/573, A61K31/706
More from Lixte Biotechnology, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12343342
Methods for treating soft tissue sarcoma
granted -
US 11931354
Formulations of oxabicycloheptanes and oxabicycloheptenes
granted -
US 11866444
Oxabicycloheptane prodrugs
granted -
US 11236102
Oxabicycloheptane prodrugs
granted -
US 10668062
Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
granted -
US 10618908
Oxabicycloheptane prodrugs
granted -
US 10532050
Formulations of oxabicycloheptanes and oxabicycloheptenes
granted
Frequently asked questions
What is US patent 10434100?
US 10434100 (Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes) is held by Lixte Biotechnology, Inc.. Status: granted. Granted Oct 8, 2019. Expires Oct 3, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10434100?
Lixte Biotechnology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 10434100 expire?
Our index shows an expiration date of Oct 3, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.